Dtr melatonin (nih cc pds) (DrugBank: Melatonin)
1 disease| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 202 | スミス・マギニス症候群 | 1 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00506259 (ClinicalTrials.gov) | July 17, 2007 | 21/7/2007 | Treatment Strategies for Children With Smith-Magenis Syndrome | A Phase One Treatment Trial of the Circadian Sleep Disturbance in Smith-Magenis Syndrome (SMS) | Developmental Delay Disorders;Chromosome Deletion;Mental Retardation;Sleep Disorders, Circadian Rhythm;Self Injurious Behavior | Drug: dTR Melatonin (NIH CC PDS);Device: Phototherapy (Bright Light);Drug: Melatonin CR | National Human Genome Research Institute (NHGRI) | NULL | Completed | 3 Years | 45 Years | All | 23 | Phase 1 | United States |